Atopic Dermatitis

• A clinical trial evaluating the efficacy and safety of the drugs - cyclosporine and methotrexate in children and adolescents with moderate t … Recruitment ended
  2023-509759-15-00 5 2021-03-15
• Long-term study to assess the safety and efficacy of Nemolizumab in subjects with Atopic Dermatitis Recruitment ended
  2024-514404-13-00 5 2020-10-01
• Evaluation of Upadacitinib in Combination with Topical Corticosteroids in Adolescent and Adult Patients with Moderate to Severe Atopic Derma … Recruitment ended
  2022-502937-24-00 5 2019-01-02
• Study to Assess the Long-term Safety of Dupilumab Administered in Participants ≥6 Months to <18 Years of Age With Atopic Dermatitis (AD). Recruitment ended
  2023-509425-53-00 5 2015-11-09
• Phase 2a study to assess the efficacy and safety of GIA632 in adult participants with moderate to severe atopic dermatitis Halted
  2025-521503-43-00 4 2026-02-12
• Phase 1 study with topical cream RLS-1496 in patients with plaque psoriasis or Eczema Ended
  2025-520514-64-00 1 2025-04-04
• A Phase 3b, Double-Blind, Multicenter, Randomized, Vehicle-Controlled, Efficacy, and Safety Study of Ruxolitinib Cream in Adults With Modera … Ended
  2023-505433-27-00 5 2024-08-13
• Efficacy and Safety of ANB032 in the Treatment of Subjects with Atopic Dermatitis Ended
  2023-503522-40-01 4 2024-04-10
• Single-dose Study of BMS-986326 at Two Dose Levels in Participants with Atopic Dermatitis Ended
  2022-502997-18-00 3 2024-02-02
• A randomized, placebo-controlled clinical trial to evaluate the safety, tolerability, pharmacokinetics, immunogenicity, pharmacodynamics and … Ended
  2023-503577-38-00 1 2023-12-07
• Moisturiser effect on the skin barrier in atopic dermatitis Ended
  2023-508560-29-00 4 2023-12-07
• A trial to evaluate the efficacy and safety of different doses of LEO 138559 in adults with moderate-to-severe atopic dermatitis. Ended
  2022-500777-14-00 4 2023-11-06
• A Phase 3b, Open-label Study to Evaluate the Effectiveness and Safety of Lebrikizumab Treatment in Adults and Adolescents with Moderate-to-S … Ended
  2023-505558-16-00 5 2023-10-24
• A Study of LY3454738 in the Treatment of Adult Participants With Moderate-to-Severe Atopic Dermatitis Ended
  2022-502888-38-00 4 2023-09-25
• To access the effect of SCD-044 in treatment of moderate to severe atopic dermatitis Ended
  2024-511615-16-00 4 2023-08-25
• A multicentre, randomised, double-blind, placebo-controlled, 12-week parallel-group trial to evaluate the efficacy and safety of oral BP1.78 … Ended
  2022-502045-10-00 4 2023-08-11
• A 2-year Open-label Extension Study to Assess the Long-term Safety and Efficacy of Lebrikizumab in Adult and Adolescent Patients with Modera … Ended
  2022-502575-30-00 5 2023-05-23
• Phase 3, 52-week Study Evaluating Rocatinlimab (AMG451)in Adolescent Subjects With Moderate-to-severe AD (ROCKET-ASTRO) Ended
  2022-501586-50-00 5 2023-05-15
• Phase 3, Placebo-controlled, Double-blind Study Assessing Rocatinlimab (AMG 451) in Combination with Topical Corticosteroids and/or Topical … Ended
  2022-501585-22-00 5 2023-05-11
• A Phase 3, Placebo-controlled, Double-blind Study Assessing Rocatinlimab (AMG 451) Monotherapy in Moderate-to-severe AD (ROCKET-Horizon) Ended
  2022-501538-44-00 5 2023-04-25
• A Phase 3, Placebo-controlled, Double-blind Study Assessing Rocatinlimab Monotherapy in Moderate-to-severe AD (ROCKET-Ignite) Ended
  2022-501540-15-00 5 2023-04-25
• A Multicenter trial to Assess the Pharmacokinetics, Safety and Efficacy of Nemolizumab in Pediatric Subjects with Moderate-to-Severe Atopic … Ended
  2024-514405-65-00 4 2021-11-22
• A Study of Baricitinib (LY3009104) in Children and Adolescents With Atopic Dermatitis (BREEZE-AD-PEDS) Ended
  2023-503898-38-00 5 2019-05-24
• Study of IMG-007 in Participants with Moderate to Severe Atopic Dermatitis Ended
  2023-505735-13-01 9

Showing 25–48 of 48 trials